Eyenovia (NASDAQ:EYEN) Posts Quarterly Earnings Results

Eyenovia (NASDAQ:EYEN) issued its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02, Zacks reports. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter last year, the business earned ($0.18) earnings per share.

Eyenovia Price Performance

EYEN opened at $0.34 on Friday. The company has a quick ratio of 0.27, a current ratio of 0.74 and a debt-to-equity ratio of 0.58. The business has a fifty day moving average of $0.50 and a 200 day moving average of $0.71. Eyenovia has a 52-week low of $0.33 and a 52-week high of $2.57. The stock has a market cap of $21.79 million, a P/E ratio of -0.47 and a beta of 1.75.

Insider Transactions at Eyenovia

In other news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the completion of the acquisition, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This trade represents a 151.85 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. William Blair upgraded shares of Eyenovia to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Wednesday.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.